We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$183M
Cap. Flow
-$318M
Cap. Flow %
-35.32%
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
34

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$25.1M
2
PEN icon
Penumbra
PEN
+$17.6M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$16.9M
4
GSK icon
GSK
GSK
+$12M
5
NUVL
Nuvalent
NUVL
+$10.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26M
2
ACLX
Arcellx
ACLX
+$21.9M
3
PODD icon
Insulet
PODD
+$20.4M
4
EOLS icon
Evolus
EOLS
+$19M
5
CRL icon
Charles River Laboratories
CRL
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$6.24B
$2.67M 0.3%
58,000
+6,000
+12% +$212K
HOLX
52
DELISTED
Hologic
HOLX
$2.43M 0.27%
+34,000
New +$2.37M
ANNX icon
53
Annexon
ANNX
$918M
$2.34M 0.26%
515,400
– –
ABBV icon
54
AbbVie
ABBV
$431B
$2.29M 0.25%
+14,800
New +$2.16M
PTGX icon
55
Protagonist Therapeutics
PTGX
$9.4B
$1.9M 0.21%
+83,000
New +$1.45M
BCYC
56
Bicycle Therapeutics
BCYC
$278M
$1.72M 0.19%
95,000
-296,800
-76% -$4.91M
YARW
57
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$1.64M 0.18%
+14,077
New +$2.19M
APLT
58
DELISTED
Applied Therapeutics
APLT
$1.54M 0.17%
460,793
-731,833
-61% -$1.82M
NRIX icon
59
Nurix Therapeutics
NRIX
$2.62B
$1.48M 0.16%
143,000
-671,000
-82% -$4.6M
YMAB
60
DELISTED
Y-mAbs Therapeutics
YMAB
$1.07M 0.12%
157,182
– –
RCEL icon
61
Avita Medical
RCEL
$146M
$1.03M 0.11%
75,000
– –
APGE icon
62
Apogee Therapeutics
APGE
$10.2B
$978K 0.11%
35,000
– –
FDMT icon
63
4D Molecular Therapeutics
FDMT
$552M
$927K 0.1%
45,748
-78,000
-63% -$1.03M
ILMN icon
64
Illumina
ILMN
$29.3B
$738K 0.08%
+5,448
New +$629K
INBX
65
DELISTED
Inhibrx, Inc. Common Stock
INBX
$570K 0.06%
15,000
-534,183
-97% -$11.4M
CSTL icon
66
Castle Biosciences
CSTL
$931M
$561K 0.06%
26,000
-257,500
-91% -$4.53M
SKIN icon
67
SkinHealth Systems
SKIN
$99.5M
$482K 0.05%
155,000
-2,651,720
-94% -$9.95M
IMUX icon
68
Immunic
IMUX
$198M
$450K 0.05%
30,000
– –
IMGN
69
DELISTED
Immunogen Inc
IMGN
$387K 0.04%
+13,050
New +$260K
ADVM
70
DELISTED
Adverum Biotechnologies
ADVM
$320K 0.04%
+42,500
New +$388K
WGS icon
71
GeneDx Holdings
WGS
$2.08B
$165K 0.02%
60,000
-721,396
-92% -$1.68M
XERS icon
72
Xeris Biopharma Holdings
XERS
$1.27B
$146K 0.02%
62,083
-242,000
-80% -$447K
LQDA icon
73
Liquidia Corp
LQDA
$7.95B
$120K 0.01%
10,000
-165,000
-94% -$1.19M
ACAD icon
74
Acadia Pharmaceuticals
ACAD
$4.9B
– –
-244,627
Closed -$5.1M
ALKS icon
75
Alkermes
ALKS
$8.11B
– –
-54,400
Closed -$1.52M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Soleus Capital Management held 107 positions worth $901M, down 17% from $1.08B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management withdrew a net $318M in Q4 2023, closing 34 positions and reducing 34 holdings. Its most notable exit was Insulet, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $27.5M.

  • Soleus Capital Management's largest Q4 2023 buy was HCA Healthcare: 101,500 shares worth $27.5M.
  • Soleus Capital Management added most to GSK in Q4 2023, an estimated $12M increase.
  • Soleus Capital Management's biggest Q4 2023 reduction was TG Therapeutics, cutting an estimated $26M.
  • Soleus Capital Management fully exited Insulet in Q4 2023, selling an estimated $20.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $901M portfolio in Q4 2023.
  • Soleus Capital Management opened 16 new positions and closed 34 in Q4 2023.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $901M.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.